DocDollars

Geistlich Pharma, North America, Inc.

NJ · United States · Reporting entity ID 100000010711

Total reported 2019–2025
$6.64M
#617 of 2,960 reporting companies — 0% of all reported industry payments
$2.40M in general payments across 12,298 records, plus $4.24M in research funding across 127 records.

How it breaks down

General payments $2,398,622
Research funding $4,244,737

Where this comes from

Figures are from the CMS Open Payments “payments grouped by reporting entity” dataset, queried live. Reporting entities are applicable manufacturers and group purchasing organisations required to report under the Sunshine Act.

Summary

Geistlich Pharma, North America, Inc. reported $6.64M to US doctors and teaching hospitals from 2019 to 2025, ranking #617 of 2,960 reporting companies. 64% of that was research funding and 36% general payments such as consulting, speaking, food and travel. 12,298 general payment records and 127 research records were filed.

Common questions about Geistlich Pharma, North America, Inc.

How much has Geistlich Pharma, North America, Inc. paid US doctors?

Geistlich Pharma, North America, Inc. reported $6,643,359 to US physicians and teaching hospitals across the 2019–2025 Open Payments program years: $2,398,622 in general payments, $4,244,737 in research funding.

How does Geistlich Pharma, North America, Inc. rank among drug and device companies?

It ranks #617 of 2,960 reporting entities by total reported value, about 0% of all industry payments in the dataset.

Does a payment from Geistlich Pharma, North America, Inc. mean a doctor did something wrong?

No. Open Payments records transfers of value such as speaking fees, consulting, meals, travel and research funding. The data shows the relationship, not its effect on prescribing or care.